{"text_format":"2","workbook":"xlsx","n_sheets":1,"sheets":["HTS drug screening"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":0,"defined_names":0,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"HTS drug screening","index":0,"n_rows":61,"n_cols":6,"rows_kept":61,"cut":false,"hidden":false,"merged":[]}
[null," Name","Target","Stock Concentration","molecular weight","Description"]
[1,"AEE788 (NVP-AEE788)","EGFR","10 mM",440.58,"AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM and also inhibits VEGFR2 and Flt with IC50 of 77 nM and 59 nM, respectively."]
[2,"Afatinib (BIBW2992)","EGFR","10 mM",485.94,"BIBW2992 (Afatinib, Tomtovok, Tovok) irreversibly  inhibits EGFR/HER2 including EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively."]
[3,"BMS-599626 (AC480)","EGFR","10 mM",567.01,"BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively."]
[4,"Erlotinib HCl","HER1/EGFR","10 mM",429.9,"Erlotinib HCl is an HER1/EGFR inhibitor with IC50 of 2 nM."]
[5,"Dacomitinib (PF299804,PF-00299804)","EGFR","10 mM",469.94,"PF299804 is a potent, irreversible pan-ErbB inhibitor against ErbB1, ErbB2 and ErbB4 with IC50 of 6 nM, 45.7 nM and 73.7 nM, respectively."]
[6,"Gefitinib (Iressa)","EGFR","10 mM",446.9,"Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively."]
[7,"Lapatinib","EGFR","10 mM",581.05999999999995,"Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively."]
[8,"Neratinib (HKI-272)","EGFR","10 mM",557.04,"Neratinib (HKI-272) is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM, respectively."]
[9,"CI-1033 (Canertinib)","EGFR, HER2","10 mM",485.94,"CI-1033 (Canertinib) is an orally bioavailable irreversible Pan-erbB tyrosine kinase inhibitor, targeting EGFR with IC50 of 0.8, 19 and 7 nM for EGFR, HER-2 and ErbB-4, respectively."]
[10,"CO-1686","EGFR","10 mM",555.54999999999995,"an irreversible, mutant-selective EGFR inhibitor with Ki of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively. Phase 1/2."]
[11,"BKM120 (NVP-BKM120)","PI3K","10 mM",410.39,"BKM120 is a selective PI3K inhibitor of p110α, p110β, p110δ and p110γ with IC50 of 52-99 nM, 166 nM, 116 nM and 262 nM, respectively."]
[12,"BYL719","PI3K","10 mM",441.47,"BYL719 strongly and selectively inhibits PI3Kα."]
[13,"XL147","PI3K","10 mM",448.52,"XL147 (SAR245408) is a selective and reversible class I PI3K inhibitor for wild type and mutant p110α with IC50 of 40 nM and 40 nM, respectively."]
[14,"Everolimus (RAD001)","mTOR","10 mM",958.52,"mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM."]
[15,"AZD2014","mTOR","10 mM",462.54,"mTOR inhibitor with IC50 of 2.8 nM; highly selective against multiple PI3K isoforms (α/β/γ/δ). Phase 2."]
[16,"PF-05212384 (PKI-587)","mTOR","10 mM",615.73,"PKI-587 is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively."]
[17,"XL765 (SAR245409)","mTOR","10 mM",599.66,"XL765 is a dual inhibitor of mTOR/PI3k for mTOR, p110α, p110β, p110γ and p110δ with IC50 of 157 nM, 39 nM, 113 nM, 9 nM and 43 nM, respectively."]
[18,"BEZ235","P3k/mTOR","10mM",469.55,"BEZ235 (NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively. Inhibits ATR with IC50 of 21 nM; shown to be poor inhibitory to Akt and PDK1. Phase 1/2."]
[19,"AZD5363","Akt all Isoform","10mM",428.92,"potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 1/2."]
[20,"ABT-199 (GDC-0199 )","Bcl-2","10 mM",868.44,"ABT-199 is a Bcl-2-selective inhibitor with Ki of < 0.010 nM."]
[21,"ABT-888 (Veliparib)","PARP","10 mM",244.29,"ABT-888 (Veliparib, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM, respectively."]
[22,"AUY922 (NVP-AUY922)","HSP (e.g. HSP90)","10 mM",465.54,"NVP-AUY922 (VER-52296) is a highly potent HSP90 inhibitor for HSP90α and HSP90β with IC50 of 13 nM and 21 nM, respectively."]
[23,"Axitinib","c-Kit","10 mM",386.47,"Axitinib (AG-013736) is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM, respectively."]
[24,"AZD4547","FGFR","10mM",463.57," novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 1/2."]
[25,"AZD6244 (Selumetinib)","MEK","10 mM",457.68,"AZD6244 (Selumetinib, ARRY-142886) is highly potent to inhibit MEK1 with IC50 of 14 nM."]
[26,"LGK-974","PORCN","10 mM",396.44,"LGK-974 is a potent and specific PORCN inhibitor, and inhibits Wnt signaling with IC50 of 0.4 nM. Phase 1"]
[27,"BGJ398 (NVP-BGJ398)","FGFR","10 mM",560.48,"BGJ398 (NVP-BGJ398) is a potent and selective inhibitor of FGFR1, FGFR2 and FGFR3 with IC50 of 0.9 nM, 1.4 nM and 1 nM, respectively."]
[28,"Bortezomib (Velcade)","Proteasome","10 mM",384.24,"Bortezomib is a potent 20S proteasome inhibitor with Ki of 0.6 nM."]
[29,"Cediranib (AZD2171)","VEGFR, Flt","10 mM",450.51,"Cediranib (AZD2171) inhibited VEGF-stimulated proliferation and KDR phosphorylation with IC50 of 0.4 and 0.5 nM, respectively. "]
[30,"Crizotinib (PF-02341066)","ALK","10 mM",450.34,"PF-2341066 (Crizotinib) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nnM, respectivley."]
[31,"Dasatinib (BMS-354825)","Bcr-Abl","10 mM",488.01,"Dasatinib (BMS-354825, Sprycel) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of ＜1 nM, 0.5 nM and 79 nM, respectively."]
[32,"Dovitinib (TKI-258)","c-Kit","10 mM",392.43,"Dovitinib (TKI258, CHIR258) is a novel multi-target inhibitor for Flt3, c-Kit, FGFR1/3, VEGFR1/2/3, PDGFRα/β with IC50 of 1 nM, 2 nM, 8 nM/9 nM and 10 nM/13 nM/8 nM, 210 nM/27 nM respectively."]
[33,"Imatinib (Gleevec)","PDGFR","10 mM",493.6,"Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively."]
[34,"INCB28060","Met"]
[35,"LDE225 (NVP-LDE225, Erismodegib)","Smoothened","10 mM",485.5,"LDE225 (NVP-LDE225) is a smoothened antagonist with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively."]
[36,"LDK378","ALK","10 mM",558.14,"potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. Phase 2."]
[37,"LEE011","CDK",null,null,"ighly specific CDK4/6 inhibitor. "]
[38,"Nilotinib (AMN-107)","Bcr-Abl","10 mM",529.52,"Nilotinib (AMN-107, Tasigna) is a Bcr-Abl inhibitor with IC50 less than 30 nM."]
[39,"Olaparib (AZD2281)","PARP","10 mM",434.46,"Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively. "]
[40,"Panobinostat (LBH589)","HDAC","10 mM",349.43,"Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM. Phase 3."]
[41,"Pazopanib HCl","VEGFR, PDGFR, c-Kit","10 mM",473.98,"Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM, respectively."]
[42,"PD 0332991 (Palbociclib) HCl","CDK","10 mM",483.99,"PD 0332991 is a highly selective inhibitor of CDK4/cyclin D1 and CDK6/cyclin D2 with IC50 of 11 nM and 16 nM, respectively."]
[43,"PF-04449913","HSP90","10 mM",521.53,"s a potent and selective HSP90 inhibitor with Kd of 41 nM and induces Her-2 degradation with IC50 of 37 nM. Phase 1/2. "]
[44,"Sotrastaurin (AEB071)","PKC","10 mM",438.48,"Sotrastaurin (AEB071) is a potent selective pan-PKC inhibitor and highly inhibits PKCθ with Ki of 0.22 nM. "]
[45,"Sunitinib Malate (Sutent)","c-Kit","10 mM",532.55999999999995,"Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit."]
[46,"Tandutinib (MLN518)","FLT3","10 mM",562.70000000000005,"Tandutinib (MLN518) is a FLT3 inhibitor. In cell-based assays tandutinib inhibited FLT3 ,PDGFR, and KIT with IC50 values of 95-122 ng/mL."]
[47,"Tivozanib (AV-951)","VEGFR, c-Kit, PDGFR","10 mM",454.86,"Tivozanib also known as AV-951 is an orally bioavailable potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively."]
[48,"Vismodegib (GDC-0449)","Hedgehog/smothen","10 mM",421.3,"GDC-0449 (Vismodegib, HhAntag691) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM."]
[49,"LY2835219","CDK","10 mM",602.70000000000005,"LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM"]
[50,"Cabozantinib (XL184)","VEGFR2,c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL ","10 mM",635.59,"Cabozantinib malate is the malate of Cabozantinib, a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM"]
[51,"Foretinib (XL880)","HGFR and VEGFR, mostly for Met and KDR","10 mM",632.65,"Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2"]
[52,"Ibrutinib","Btk,modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, ErbB2, JAK3","10 mM",440.5,"brutinib is a potent and highly selective Btk inhibitor with IC50 of 0.5 nM, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3"]
[53,"vemurafenib","B-RafV600E","10 mM",489.92,"Vemurafenib (PLX4032, RG7204) is a novel and potent inhibitor of B-RafV600E with IC50 of 31 nM"]
[54,"trametinib","MEK1/2","10 mM",615.39,"Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Phase 3."]
[55,"dabrafenib","BRAFV600","10 mM",519.55999999999995,"Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively. Phase 3"]
[56,"regorafenib","VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1","10 mM",482.82,"Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM"]
[57,"bosutinib"," dual Src/Abl","10 mM",530.45000000000005,"Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively"]
[58,"carfilzomib","Proteasome","10 mM",719.91,"Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities"]
[59,"Ruxolitinib","JAK1/2","10 mM",306.37,"INCB018424 is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. Phase 3."]
[60,"vandetanib","VEGFR","10 mM",475.35,"Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM"]